ripasudil + brimonidine

A **combination ophthalmic therapy** of the Rho kinase inhibitor **ripasudil** and the alpha-2 adrenergic agonist **brimonidine**, administered as an eye drop, primarily for the **treatment of glaucoma** and intraocular hypertension. Ripasudil reduces intraocular pressure (IOP) by inhibiting Rho kinase to enhance aqueous humor outflow through the trabecular meshwork, while brimonidine decreases aqueous humor production and increases uveoscleral outflow via alpha-2 adrenergic receptor agonism. Preclinical and clinical studies show that the combination yields **additive IOP-lowering effects** compared to either component alone, and may also confer **neuroprotection** of retinal ganglion cells via modulation of multiple signaling pathways in the retina. The fixed-dose combination may improve patient adherence and convenience relative to both agents administered separately[1][2][3].

Brand names

GLA-ALPHA

Other names

brimonidine + ripasudil